Live Companies House data temporarily unavailable

Companies House is rate-limiting or unreachable right now, so this page is showing the last data we hold on file. Officers, charges and filing history may be missing or out of date — refresh in a few minutes for live figures.

UROPHARMA, INC.

💤Zombieactive
FC035512 · Other company type · incorporated 2017-08-10
Investment thesis
Zombie company — trading but stalled; unlikely mover.
Why interesting: Quiet, steady; could be a succession or carve-out candidate with the right conversation.
Why risky: No growth signal; thin margin for error on price.
🔒Estimated value
—
Upgrade to see
Turnover
—
not disclosed
Net worth
—
book net assets
Opportunity
67/100
Strong
🔔
Follow this company (free)
Email alerts on filings, charges, director changes, gazette notices. No account needed.

Unsubscribe any time from any email. GDPR-respectful.

🔒Generate AI memo →🔒Outreach pack →🔒Corporate story →📑 Reports →Sign in to watch
Investor take
Pursue
Active trading company. Reasonable fundamentals — worth a memo before deciding.

Opportunity 67/100 (strong), bankability 75/100. Most likely exit: share sale to pe / searcher (58/100).

Data confidence

Overall: none (22/100)

Very limited data. Most AI-generated insights cannot be produced or should be considered unreliable.

Company profile
no address, no SIC, incorporation date
55
Financials
No iXBRL financials extracted
0
Lenders & charges
No charge records returned
50
Directors & officers
No officers data
0
Ownership & PSC
No PSC data returned
40
Director network
Network not yet resolved
30
Filing history
No filing history
0
Gazette notices
No matching gazette notices (standard for active companies)
60
Opportunity Score
67/100Strong
PassWatchWorth a lookStrongExceptional 

Solid opportunity signal. Worth a dedicated memo and management meeting.

Business quality
65
Adequate — check latest filings for context.
Acquirability
50
Some acquirability indicators.
Risk profile
85
Few red flags.
Signal strength
60
Adequate data — full accounts will sharpen view.
Corporate timeline (1 events)Click to expand
  1. 2017-08-10
    🏢
    Company incorporated
    As UROPHARMA, INC.

Owner dependency

55/100
Moderate — manageable with handover

Some founder dependency, but not acute. A structured handover period should cover most risk.

FACTORS
  • +No director turnover: Company is 9 years old with no director changes — suggests a very tight-knit founder team never broadened.

Succession & seller-readiness

30/100
Weak signal

Limited succession signal. Not a near-term off-market candidate.

Red flags

clean
No red flags detected from available public data. (This is not a clean bill of health — detailed accounts review still recommended.)
🔒Tailored diligence questions

6 specific questions generated from this company's actual signals — liquidity, leverage, director age, charge count, red flags, age-of-company.

Available from the Pro tier upwards.

See pricing →
🔒Advanced scoring suite

Exit-route ranking, improvement thesis, quiet-distress detector, covenant-pressure proxy, extraction monitor, approaching triggers, ownership drift, local cluster, value trap, debt capacity, archetype classification — 48+ scoring modules.

Available from the Pro tier upwards.

See pricing →

Company details

Statusactive
TypeOther company type
Incorporated2017-08-10
JurisdictionUNITED STATES
Primary SIC—

Registered office

CORPORATION TRUST CENTRE 1209 ORANGE STREET
WILMINGTON
NEW CASTLE COUNTY
DELAWARE 19801

Filing status

Accounts
Next due: —
Last made up to: 2024-12-31
Confirmation statement
Next due: —
Last: —